amikacin

amikacin. It is a semi-synthetic aminoglycoside antibiotic derived from kanamycin A, primarily used to treat severe bacterial infections caused by susceptible Gram-negative bacteria. Developed to combat resistance to earlier agents, it is often reserved for serious hospital-acquired infections like sepsis, pneumonia, and complicated urinary tract infections, particularly those involving Pseudomonas aeruginosa. Its use is typically guided by susceptibility testing due to potential toxicity and the rise of resistant pathogens.

Medical uses

Amikacin is indicated for the treatment of serious infections due to susceptible strains of Gram-negative bacteria, including those resistant to gentamicin and tobramycin. It is commonly employed in the management of bacteremia, nosocomial pneumonia, and infections in neutropenic patients, often in combination with a beta-lactam antibiotic like piperacillin for synergistic effect. It is also a key component in the treatment of Mycobacterium avium complex infections, particularly in patients with AIDS, and is used in certain regimens for multidrug-resistant tuberculosis. Administration is typically via intravenous infusion or intramuscular injection in a hospital setting.

Adverse effects

The most significant adverse effects are dose-related ototoxicity, which can manifest as irreversible vestibular dysfunction or hearing loss, and nephrotoxicity, potentially leading to acute kidney injury. Risk factors include prolonged therapy, high peak concentrations, concurrent use of other nephrotoxic agents like vancomycin or furosemide, and pre-existing renal impairment. Other potential effects include neuromuscular blockade, which may potentiate the effects of anesthetic agents, and rare hypersensitivity reactions. Monitoring of serum creatinine and therapeutic drug monitoring are essential to mitigate these risks.

Mechanism of action

Amikacin exerts its bactericidal effect by binding irreversibly to the bacterial 30S ribosomal subunit, specifically to the 16S rRNA component within the A-site of the ribosome. This binding interferes with the initiation complex of protein synthesis and causes misreading of the messenger RNA template, leading to the incorporation of incorrect amino acids and the production of nonfunctional or toxic polypeptides. The drug is actively transported across the bacterial cell membrane via an oxygen-dependent process, making it less effective against anaerobic organisms. This mechanism is shared with other aminoglycosides like streptomycin.

Pharmacokinetics

Following parenteral administration, amikacin is not absorbed from the gastrointestinal tract and achieves peak serum concentrations within one hour. It distributes primarily in the extracellular fluid and exhibits poor penetration into the cerebrospinal fluid, except when the meninges are inflamed. The drug is not metabolized and is excreted unchanged almost entirely by glomerular filtration in the kidneys, with a half-life of approximately 2-3 hours in patients with normal renal function. This half-life is significantly prolonged in conditions like renal failure, necessitating dosage adjustment based on creatinine clearance.

Spectrum of activity

Amikacin possesses a broad spectrum of activity against aerobic Gram-negative bacilli, including members of the Enterobacteriaceae family such as Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae. It is notably effective against Pseudomonas aeruginosa and certain Acinetobacter species. Its activity against Gram-positive bacteria is limited, though it may show some effect against Staphylococcus aureus. A key advantage is its stability against many bacterial aminoglycoside-modifying enzymes like acetyltransferases and phosphotransferases that inactivate older agents, granting it utility against strains resistant to tobramycin and gentamicin.

History and society

Amikacin was developed in the early 1970s by researchers at the Bristol-Myers Squibb pharmaceutical company, specifically by a team led by Hamao Umezawa, who had also discovered kanamycin. It was designed through chemical modification of the kanamycin A molecule to resist inactivation by bacterial enzymes that were becoming prevalent in clinical settings. The drug received approval from the U.S. Food and Drug Administration in 1976. Its introduction provided a critical therapeutic option during an era of increasing antimicrobial resistance, and it remains on the World Health Organization's List of Essential Medicines as a reserve agent for serious infections.